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Abstract
Drug–target binding kinetics (as determined by association and dissociation rate constants, kon and koff) can be an important
determinant of the kinetics of drug action. However, the effect compartment model is used most frequently instead of a
target binding model to describe hysteresis. Here we investigate when the drug–target binding model should be used in lieu
of the effect compartment model. The utility of the effect compartment (EC), the target binding kinetics (TB) and the
combined effect compartment–target binding kinetics (EC–TB) model were tested on either plasma (ECPL, TBPL and EC–
TBPL) or brain extracellular fluid (ECF) (ECECF, TBECF and EC–TBECF) morphine concentrations and EEG amplitude in
rats. It was also analyzed when a significant shift in the time to maximal target occupancy (TmaxTO) with increasing dose,
the discriminating feature between the TB and EC model, occurs in the TB model. All TB models assumed a linear
relationship between target occupancy and drug effect on the EEG amplitude. All three model types performed similarly in
describing the morphine pharmacodynamics data, although the EC model provided the best statistical result. The analysis
of the shift in TmaxTO (DTmaxTO) as a result of increasing dose revealed that DTmaxTO is decreasing towards zero if the
koff is much smaller than the elimination rate constant or if the target concentration is larger than the initial morphine
concentration. The results for the morphine PKPD modelling and the analysis of DTmaxTO indicate that the EC and TB
models do not necessarily lead to different drug effect versus time curves for different doses if a delay between drug
concentrations and drug effect (hysteresis) is described. Drawing mechanistic conclusions from successfully fitting one of
these two models should therefore be avoided. Since the TB model can be informed by in vitro measurements of kon and
koff, a target binding model should be considered more often for mechanistic modelling purposes.
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Introduction
Drug–target binding kinetics is an important criterion in the
selection of drug candidates, as it can be a determinant of
the time course and the selectivity of drug effect [1–4].
However, the in vivo time course of drug action is
influenced by multiple factors including plasma pharma-
cokinetics, target site distribution, target binding kinetics,
competition with endogenous ligands, turnover of the tar-
get, signal transduction kinetics and the kinetics of home-
ostatic feedback. As a consequence, the influence of
binding kinetics on drug action can only be understood in
conjunction with these kinetic processes and its relevance
is still not fully understood and subject to an ongoing
debate [3, 5–8].
One of the arguments against an important role of
binding kinetics for in vivo drug action is that binding
kinetics are most often not required to get a good fitting
PKPD model for small molecules. However, numerous
examples are available were binding kinetic models have
been successfully applied, and binding kinetics are rou-
tinely incorporated in models for biologics and PET data
[9–17]. The sparsity of target binding PKPD models for
small molecules can be explained by the relatively fast
binding kinetics of many drugs currently on the market,
compared to their pharmacokinetics [3]. In addition, when
a delay between drug concentrations and effect is observed,
this delay is often described by an effect compartment or
indirect response model [18, 19].
Here we study the difference between the effect com-
partment (EC) model, the target binding (TB) model, the
direct effect (DE) and the indirect effect (IE) model, which
are described below. The EC model describes the delay
between pharmacokinetics (PK) and pharmacodynamics
(PD) by including first order distribution of the drug into
and out of a hypothetical target-site (biophase) compart-
ment, which drives the pharmacodynamics [20]. The
indirect effect (IE) model describes the delay between
pharmacokinetics and pharmacodynamics by the zero order
synthesis and first order degradation of an effector mole-
cule which represents the pharmacodynamics [21]. The
target binding (TB) model describes the delay between
pharmacokinetics and pharmacodynamics by the second
order drug–target association and first order dissociation of
the drug–target complex [22–24]. The DE model describes
no delay between the pharmacokinetics and pharmacody-
namics and links the drug concentration directly to the
effect measurements. All of these models can account for
saturation of the PK–PD relationship (i.e. increasing drug
concentrations do not increase the drug effect beyond a
certain concentration), but this saturation can occur at
different steps in the process between the drug
concentration and the drug effect. For the EC model, the
relationship between drug concentrations in the effect
compartment and the effect can be saturable. For the IE
model, both the relationship between the drug concentra-
tion and the synthesis or degradation rate of the effector
molecule can be saturable. For the TB model, the rela-
tionship between the drug concentration and the target
occupancy is saturable and the relationship between target
occupancy and effect can be saturable. For the DE model,
the relationship between the drug concentration and the
drug effect can be saturable.
These models thus result in a zero, first and second order
formation of the the pharmacodynamics in the EC, TB and
IE model, respectively. This results in different dose
dependencies of the time to the maximal effect (TmaxPD).
As a current paradigm, the shift in TmaxPD (DTmaxPD) in a
PKPD dataset as a consequence of a change in the dose
identifies the appropriate PKPD model to describe the data:
with increasing dose, the TmaxPD can increase for the
indirect response model, decrease for the TB model and is
constant for the EC model [25–27].
However, in contrast to common belief, the indirect
response model does not always result in an increasing
TmaxPD with increasing doses but can also give rise to a
decreasing TmaxPD with increasing doses, as shown by
Peletier et al. [28]. If the relationship between target
occupancy and effect is not delayed and monodirectional
(i.e. an increase in target occupancy never results in a
decrease in effect and vice versa), the TmaxPD coincides
with the time to the maximal target occupancy (TmaxTO).
To start with this most simple situation, we focus in this
paper only on the TmaxTO. A comprehensive analysis of
the conditions for which a shift in TmaxTO for changing
doses occurs in a TB model is currently not available. It
might be that EC models have been used while TB models
could have been applied equally well to describe the data in
previous PKPD studies.
One example in which performance of TB and EC
models has been investigated indicates comparable per-
formance in describing the data of eight calcium channel
blockers, but this study used only one dose level for all
drugs [14] and therefore cannot be used to validate the
relationship between dose and DTmaxPD. An additional
complexity in choosing the most appropriate PKPD model
to describe PKPD data is that, for most drugs, factors as
target site distribution, drug–target binding and turnover of
signaling molecules occur in parallel. It is not always
needed to incorporate all these factors in the PKPD model,
as only the rate limiting mechanism is required for a proper
model fit that describes the observed data. However,
leaving out such factors will never lead to understanding of
the individual contributions and the interplay between
these factors. Combined EC–TB models [13, 29, 30] as
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well as combined IE–TB models [10] have been applied
successfully to discriminate between the contributions of
separate factors. However, this discrimination is not always
possible if one of the factors is relatively fast and does not
contribute significantly to the delay between pharmacoki-
netics and pharmacodynamics [31–33]. In short, the rele-
vance of drug–target binding kinetics cannot be excluded if
one of the other models is successfully fitted to a dataset,
and there is a need to generate more insight into the dif-
ference between the TB model and the EC model.
The aim of the current study is to investigate if the TB
and EC model can give similar drug effect versus time
curves and under what conditions this will occur. In this
study, a historical PKPD dataset for morphine was used
[34] to compare the goodness of fit for the TB model with
the EC model and the combined EC–TB model in
describing the time course of the EEG effect following
administration of three different doses of morphine (4, 10
and 40 mg/kg). Both plasma and brain extracellular fluid
(ECF) drug concentrations were measured and tested in
this study to be connected to the pharmacodynamics via an
EC, TB or EC–TB model. Subsequently, a more general
insight in the shift of TmaxTO (DTmax TO) for different
dose levels in the drug–target binding model is obtained to
identify for what parameter values the TB model can be
discriminated from the EC model based on the DTmaxTO.
To that end, comprehensive simulations and mathematical
model analysis was performed for a wide range of drug–
target association and dissociation rate constants, for var-
ious plasma elimination rate constants, target concentra-
tions, and dose levels.
Methods
Pharmacokinetic and pharmacodynamic (PKPD)
data of morphine in rats
All pharmacokinetics and pharmacodynamics data used in
this study were obtained from the experiments described
earlier [35]. In short: Morphine was intravenously admin-
istered to Male Wistar rats, during a 10-min infusion, in 4
different dose groups: 0, 4, 10 or 40 mg/kg with 5, 29, 11
and 14 animals, respectively. The P-glycoprotein (Pgp)
inhibitor GF120918 or vehicle was given as a continuous
infusion. In the group of 29 animals that received 4 mg/kg
morphine, 9 animals received GF120918, the other 20
animals received the vehicle. Furthermore, while plasma
concentrations were measured in all animals, brain ECF
concentrations were measured with microdialysis in 29
animals, of which 15 received 4 mg/kg, 0 received 10 mg/
kg, 9 received 40 mg/kg and 5 received 0 mg/kg morphine,
see also Table 1.
For the modelling data set, all data entries without time
recordings, without concentration data or with concentra-
tion data equal to 0 were removed from the dataset. The
lower limit of quantification for morphine in plasma sam-
ples was 88 nM and 1.75 nM for morphine in ECF sam-
ples. The pharmacodynamics of morphine was measured as
the amplitude in the d frequency range (0.5–4.5 Hz) of the
EEG and recorded every minute. The EEG data were fur-
ther averaged for every 3-min interval to reduce the noise
and decrease the model fitting time.
General model fitting methods
Data fitting was based on minimization of the objective
function value (OFV = - 2 * log likelihood) as imple-
mented in NONMEM 7.3 [36]. Simulations and visuali-
sations were performed in RStudio version 3.4.0. To
account for the number of parameters for the comparison of
non-nested models, the Akaike Information Criterion
(AIC) was calculated by adding two times the number of
estimated parameters to the OFV [37]. Variability in the
data was described by IIV (Inter Individual Variability:
variability in parameter values between animals) and a
residual error term. IIV was implemented assuming a log-
normal distribution according to Eq. 1:
Pi ¼ Ppop  egi ð1Þ
In which Pi is the individual parameter value, Ppop is the
typical parameter value in the population and gi is normally
distributed around a mean of zero with variance x2
according to Eq. 2:
giN 0;x2
  ð2Þ
The remaining variation between the data and the model
predictions are incorporated as residual error for which
both a proportional (Eq. 3) and a combined proportional
and additive (Eq. 4) error model were tested.
obsij ¼ predij  1 þ eprop;ij
  ð3Þ
obsij ¼ predij  1 þ eprop;ij
 þ eadd;ij ð4Þ
In these equations, obsij is the observation, predij is the
model prediction, eprop,ij is the proportional error and eadd,ij
is the additive error for individual i at time point j. Both
eprop,ij and eadd,ij are normally distributed around a mean of
zero with variance r2 according to Eqs. 5 and 6:
eprop;ijN 0; r2prop
  ð5Þ
eadd;ijN 0; r2add
 
: ð6Þ
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Morphine plasma pharmacokinetics modelling
One-compartment, two-compartment and three-compart-
ment models were fitted to the plasma pharmacokinetics
data, with both proportional and additive plus proportional
error models, and with IIV on the various parameters. The
differential equations and model scheme are given in
Supplement S1. The best fits (based on AICs) of each
structural model were compared for their Goodness Of Fits
(GOFs) and AICs. Since the purpose of the plasma phar-
macokinetics modelling was to get the best possible input
for the pharmacodynamics modelling, GOF was assessed
by the AIC and by individual fits. Over- or underestimation
of IIV and population parameter estimates and high
uncertainties in population parameter estimates were not
regarded as problematic, since only the right individual
parameter estimates were required for pharmacodynamics
modeling.
Morphine brain ECF pharmacokinetics Modelling
The individual parameter estimates that were estimated to
describe the plasma pharmacokinetics were used as fixed
parameters to describe the plasma pharmacokinetics profile
as input for the brain ECF concentrations. To describe the
ECF concentrations, we thus assumed that the distribution
of the drug into and out of the ECF did not lead to a change
in plasma concentrations. The differential equations and
model scheme are given in Supplement S1. The best fits,
based on the AICs, of each structural model were compared
for their GOFs and AICs. Since the purpose of the brain
ECF pharmacokinetics modelling was to get the best pos-
sible input for the pharmacodynamics modelling, GOF was
assessed by the AIC and by individual fits. Over- or
underestimation of IIV and population parameter estimates
and high uncertainties in population parameter estimates
were not regarded as problematic, since only the right
individual parameter estimates were required for pharma-
codynamics modeling.
EEG pharmacodynamics modelling
To maximize the identifiability of the pharmacodynamics
model parameters, all pharmacokinetic parameters were
used as fixed parameters to describe the plasma and brain
ECF concentrations as input for all the described pharma-
codynamics models to describe EEG effects [38]. The
different type of models that were tested are outlined in
Table 2. The differential equations are given in Supple-
ment S1. For each model, the most informative variations
on the model structure are given in the results section.
To compare structural models that linked plasma or
brain ECF concentrations directly to the PD, the models
that used plasma pharmacokinetics were fitted to the
reduced dataset that only contained animals with plasma
PK, brain ECF and EEG measurements. Model comparison
was based on the AIC, visual inspection of the GOF and a
VPC (Visual Predictive Check) to check if the IIV was
captured appropriately.
Drug–target binding model simulations
Simulations with a one-compartment binding model with
IV administration were performed for a wide range of kon
Table 1 Overview of treatment groups and data collection
Morphine dose Pgp inhibitor Plasma pharmacokinetics data ECF pharmacokinetics data EEG data Dosed animals
0 mg/kg - 0 5 5 5
4 mg/kg - 20 7 16 20
4 mg/kg ? 9 8 9 9
10 mg/kg - 11 0 11 11
40 mg/kg - 14 9 13 14
Total 54 29 54 59
Table 2 Overview of the different model types, the data that were
used and the model numbers as used in this manuscript
Model type Concentrations linked to effect Model number
EC Plasma ECPL1 – ECPL4
EC ECF ECECF1
TB Plasma TBPL1–TBPL5
TB ECF TBECF1
EC–TB Plasma ECTBPL1–ECTBPL5
IE ECF IEECF1
DE ECF DEECF1
EC effect compartment, TB target binding, EC–TB effect compart-
ment–target binding, IE indirect effect, DE direct effect, ECF brain
extracellular fluid
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and koff values and for a variety of elimination rate con-
stants, target concentrations and drug dose levels (Table 3).
The TmaxTO was compared for two different doses to
determine the influence of the drug dose on the TmaxTO.
The DTmaxTO values were calculated by subtracting the
TmaxTO of the highest dose from the TmaxTO of the lowest
dose and DTmaxTO was plotted against kon and koff.
Results
Morphine pharmacokinetics modelling
Modelling of morphine pharmacokinetic data in plasma
and brain ECF as described in Supplement S1 identified
very similar model structures as previously described for
pharmacokinetic modelling of the same dataset by Groe-
nendaal and coworkers [35]. In short, the plasma concen-
trations were described by a three-compartment model and
the ECF concentrations were described by passive distri-
bution into and out of the brain combined with saturable
active influx and first-order efflux.
EEG pharmacodynamics modelling
ECPL model fitting
EC and TB models have been applied to the morphine data
to describe the relationship between the observed plasma
concentrations and EEG amplitude and direct effect (DE),
indirect effect (IE), EC and TB models have been applied
to brain ECF and EEG amplitude data. The differential
equations for these models are given in Supplement S1.
Firstly, the originally published ECPL model structure was
optimized by adding a slope-parameter, which describes
the linear decline of EEG amplitude over time during the
experiment independently of the drug effect, and by
including IIV on the baseline EEG amplitude only. For this
model, a transit compartment was required between the
plasma and the effect compartment for the best description
of the data [34]. An overview of the different variations on
this basic model structure is given in Table 4. The structure
of all ECPL is identical and is depicted in Fig. 1. Based on
the AIC, the parameter estimates and the GOF, model
ECPL1 was chosen as the best parameterization for the
effect compartment model in Fig. 1.
TBPL model fitting
The TBPL model was applied to describe target binding
from plasma, all TBPL models in Table 5 shared the same
structure as represented in Fig. 2. The parameter estimation
results are given in Table 5. Since the target concentration
is of influence only if it is similar to the drug concentration
(which is mostly above 100 nM in plasma and in brain
ECF, as shown in Supplement S1), the target concentration
could not be estimated in this model and was fixed to an
arbitrary low value of 1 nM in the model estimations. This
low target concentration prevents the influence of the target
concentration on the EEG amplitude in the model. The
influence of blocking Pgp has been incorporated by esti-
mating separate parameter values with and without the
presence of Pgp blocker. While the influence of blocking
Pgp on the koff or KD is mechanistically not plausible, the
improved model fits for the models which incorporate these
influences might indicate that the estimated koff and KD
values refer to apparent values which include not only the
molecular properties. The target occupancy is linearly
related to the EEG amplitude in model TBPL1–TBPL5, as
nonlinear relationships could not be identified accurately in
this study. On basis of the objective function values, model
TBPL4 was selected as the best drug–target binding model.
It should be noted that the AIC of model TBPL4 is 338
points higher than model ECPL1, which means that model
ECPL1 performs better in fitting the data. All TBPL models
have one compartment less than the transit–EC models
ECPL1–ECPL4. Therefore, the combined EC–TBPL models
EC–TBPL1 to EC–TBPL5 were developed.
EC–TBPL model fitting
The EC–TBPL model structure that was tested to describe
the EEG data is shown in Fig. 3. This model enables the
comparison between the target binding and effect com-
partment mechanism, as both models have an additional
compartment between the plasma compartment and the
compartment that is linked directly to the effect. The
parameter values, OFVs and AICs are given in Table 6.
Parameter values and objective function values of the tes-
ted EC–TBPL models describing the EEG data, based on
plasma concentrations. CV denotes the coefficient of
variation as percentage. OFV denotes the Objective
Function Value, AIC denotes the Akaike Information Cri-
terion. x2 and r2 denote the variances of the exponential
Table 3 Overview of the different simulation scenarios
Simulation # kel (1/h) Rtot (nM) C0 low (* KD) C0 high (* KD)
1 0.03 0.1 0.5 5
2 0.03 0.1 5 50
3 0.03 10 0.5 5
4 0.3 0.1 0.5 5
For each simulation, kon and koff varied between 10
-3 and 103/nM/h
and between 10-3 and 103 h-1, respectively
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IIV distribution and the proportional error distribution,
respectively. Model EC–TBPL1 was selected as best model
on basis of the AIC, but this AIC is still 39 points higher
than Model ECPL1. The uncertainty in the parameter esti-
mate of the KD in the presence of the Pgp blocker (KD–
Pgp) is rather high with 93%, but this was allowed to test
the conclusion that none of the binding models (TBPL1–
TBPL5 and EC–TBPL1 to EC–TBPL5) yielded lower AICs
than the best effect compartment model (ECPL1) in a
conservative manner.
ECECF, TBECF, IEECF and DEECF model fitting
The last models that were fitted to the EEG data were based
on the ECF concentrations instead of the plasma concen-
trations. Various model structures were tested, as shown in
Fig. 4. To compare the model fits based on ECF concen-
trations (ECECF1, TBECF1, IEECF1 and DEECF1) with the
model fits that were based on plasma concentrations (ECPL,
TBPL and EC–TBPL), the best plasma model (ECPL1) was
fitted to the limited dataset that included only animals with
ECF data. This model fit was compared to the ECF-based
model fits on basis of their AICs, as shown in Table 7.
Of all the models that are described above, model ECPL1
has the lowest AIC. To evaluate its performance in more
detail, the most relevant diagnostic plots are given in
Figures S6–S10. These diagnostic plots indicate that the
main trend of the data is captured, although the obtained fit
is not optimal (which is especially clear from Figure S10).
The small difference in AIC between the best combined
EC–TB model (EC–TBPL1) and the best EC model
Table 4 Parameter values and objective function values of the tested EC models describing the EEG data, based on plasma concentrations
Parameter definition ECPL1 selected
model
ECPL2 no
slope
ECPL3
k1e = keo
ECPL4 no Pgp
effect
OFV 44,748.0 45,084.2 44,853.3 44,868.4
AIC 44,770.0 45,104.2 44,871.3 44,886.4
Parameter Parameter definition Value (%CV) Value
(%CV)
Value (%CV) Value (%CV)
k1e(/min) Distribution to transit compartment 0.0393 (18) 0.0432 (10) 0.0403 (10) 0.0375 (8)
keo(/min) Distribution from effect compartment 0.0382 (14) 0.0458 (9) – 0.0375 (8)
k1e–Pgp (/
min)
Distribution to transit with Pgp blocker 0.0565 (44) 0.0661 (38) 0.0295 (18) –
keo–Pgp (/
min)
Distribution from effect with Pgp blocker 0.016 (46) 0.0203 (20) – –
E0 (lV) Baseline EEG amplitude 45.1 (4) 42.2 (4) 45.8 (4) 45.9 (4)
Emax (lV) Maximal increase in EEG amplitude 27.9 (23) 25.3 (16) 26.1 (18) 27.0 (18)
EC50 (nM) concentration giving half-maximal increase in EEG
amplitude
1270 (52) 1220 (31) 912 (37) 1000 (37)
NH Hill factor 1.44 (43) 2.02 (27) 1.46 (36) 1.37 (33)
slope (lV/
min)
Increase in baseline EEG over time - 0.024 (22) 0 FIX - 0.0263
(15)
- 0.0267 (15)
x2 E0 (lV) IIV variance on E0 0.111 (20) 0.125 (19) 0.115 (20) 0.116 (20)
r2 prop Variance of proportional error 0.0554 (7) 0.0584 (7) 0.0562 (6) 0.0564 (6)
Fig. 1 Schematic representation of the ECPL model structure that was
used to describe the morphine EEG amplitudes over time. kie, first-
order in- and outward distribution rate constant for the transit
compartment. keo, first-order outward distribution rate constant from
the effect compartment. The effect compartment concentrations were
linked to the EEG amplitude by a sigmoidal Emax model. The
distribution from plasma to the tissue compartments and the brain
ECF compartment is described in Supplement S1. The arrows indicate
morphine flows, the dotted line indicates a direct relationship
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(ECPL1) is also reflected by very similar VPC results, as
shown in Figure S11. Moreover, the best model with only
binding from plasma (TBPL4) also provided a similar VPC
result (see Figure S12).
Dose-dependency of TmaxTO in a TBPL model
Simulations of drug-target binding in a TBPL model for the
range of the most relevant binding kinetics demonstrated
that the observable influence of dose on TmaxTO, which
discriminates the TB model from the EC model, is limited
to a confined range of kon and koff combinations. As visu-
alized in Fig. 5, if the koff has a value around the elimi-
nation rate constant of 0.03/h, DTmaxTO is maximal. Also,
the initial drug concentration C0 should not be above a
specific threshold value which is approximately equal to
the target concentration. The absolute DTmaxTO for dif-
ferent doses (as shown in Fig. 5) will be most relevant for
the identification of the dose-dependent DTmaxTO in a
PKPD modelling study. However, for the understanding of
the underlying determinants of this shift in DTmaxTO, the
ratio of the DTmaxTO values belonging to the two doses
should also be considered, as shown in Fig. 6. For example,
if the two different TmaxTO values obtained from the two
doses are 1 and 3 min, their ratio is 3, but the absolute
difference is 2 min. If the two TmaxTO values are 1 and
3 h, their ratio is still 3, but the difference is now 2 h. In
this latter case, the influence of the dose on the TmaxTO
will be more easily identified. Representative example
simulations that can help to understand the characteristics
of Fig. 5 are provided in Supplement S2.
Interestingly, the relationship between the DTmaxTO,
the elimination rate constant, the target concentration and
the dose could be approximated mathematically for the
upper region, the lower-left region and the lower-right
region of Fig. 5 as presented in Supplement S3. From this
analysis, it follows that for the upper half of Fig. 5, where
the koff is much larger than the kel, TmaxTO is always small,
and a significant DTmaxTO will thus not be observed. For
Table 5 Parameter values and objective function values of the tested TBPL models describing the EEG data, based on plasma concentrations
Parameter definition TBPL1 no Pgp effect
slope = 0
TBPL2 no Pgp
effect
TBPL3 Pgp on
koff
TBPL4 selected
model
TBPL5
slope = 0
OFV 45,677.7 45,170.1 45,166.6 45,092.1 45,536.9
AIC 45,689.7 45,184.1 45,182.6 45,108.1 45,550.9
Parameter Parameter definition Value (%CV) Value (%CV) Value (%CV) Value (%CV) Value
(%CV)
koff (/min) Dissociation rate constant 0.017 (8) 0.0103 (13) 0.0109 (17) 0.009 (26) 0.0149 (15)
koff–Pgp (/
min)
Dissociation rate constant with
Pgp blocker
– – 0.0087 (26) – –
KD (nM) Equilibrium constant 1980 (37) 995 (36) 935 (37) 1570 (59) 3610
KD–Pgp
(nM)
Equilibrium constant with Pgp
blocker
381 (88) 715
E0 (lV) Baseline EEG amplitude 42.4 (4) 45.9 (4) 45.8 (4) 45.4 (4) 42.2
Emax (lV) Maximal increase in EEG
amplitude
32.2 (14) 29.3 (13) 28.9 (13) 32.9 (20) 38.9
Rtot (nM) Target concentration 1 FIX 1 FIX 1 FIX 1 FIX 1 FIX
slope (lV/
min)
Increase in baseline EEG over
time
0 FIX - 0.0313 (13) - 0.0315
(12)
- 0.0299 (12) 0 FIX
x2 E0 (lV) IIV variance on E0 0.135 (18) 0.117 (20) 0.117 (20) 0.113 (19) 0.13 (17)
r2 prop Variance of proportional error 0.0639 (6) 0.059 (6) 0.059 (6) 0.0584 (6) 0.0626 (6)
Fig. 2 Schematic representation of the TBPL model structure that was
used to describe the morphine EEG amplitudes over time. kon is the
second-order drug-target association rate constant. koff is the first-
order drug-target dissociation rate constant. Target occupancy is
linearly related to the EEG amplitude. The distribution from plasma
to the tissue compartments and the brain ECF compartment is
described in Supplement S1. The arrows indicate morphine flows, the
dotted line indicates a direct relationship
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the lower and the lower-right part of Fig. 5, where the koff
is much smaller than the kel, it is found that TmaxTO does
not depend on the dose. More specifically, when the initial
drug concentration is much lower than the target concen-
tration (and koff is smaller than kel), the TmaxTO is merely
determined by the kel. On the other hand, when the initial
drug concentration is much larger than the target concen-
tration (and koff is smaller than kel), the TmaxTO is given by
a relation between koff and kel. This relationship between
the DTmaxTO, the elimination rate constant, the target
concentration and the dose is illustrated in Fig. 7.
Fig. 3 Schematic representation of the EC–TBPL model structure that
was used to describe the morphine EEG amplitudes over time. kon is
the second-order drug-target association rate constant. koff is the first-
order drug-target dissociation rate constant. keo is the first-order
distribution rate constant into and out of the effect compartment.
Target occupancy is linearly related to the EEG amplitude. The
distribution from plasma to the tissue compartments and the brain
ECF compartment is described in Supplement S1. The arrows indicate
morphine flows, the dotted line indicates a direct relationship
Table 6 Parameter values and objective function values of the tested EC–TBPL models describing the EEG data, based on plasma concentrations
Parameter definition EC–TBPL1
selected model
EC–TBPL2 no
Pgp effect
EC–TBPL3 Pgp
on keo
EC–TBPL4
koff = 1
EC–TBPL5
slope = 0
OFV 44,790.9 44,880.3 44,873.8 45,008.2 45,235.3
AIC 44,808.9 44,896.3 44,891.8 45,024.2 45,251.3
Parameter Parameter definition Value (%CV) Value (%CV) Value (%CV) Value
(%CV)
Value (%CV)
koff (/min) Dissociation rate constant 0.0275 (14) 0.0243 (14) 0.0247 (14) 1 FIX 0.0400 (9)
keo (/min) Distribution rate constant to effect
compartment
0.0327 (17) 0.0365 (12) 0.0389 (14) 0.0162 (28) 0.036 (13)
keo–Pgp (/
min)
Distribution to effect compartment
with Pgp blocker
– – 0.0265 (31) – –
KD (nM) Equilibrium constant 1520 (34) 1150 (30) 1110 (30) 2110 (50) 3150 (36)
KD–Pgp
(nM)
Equilibrium constant with Pgp
blocker
296 (93) – – 385 (78) 594 (47)
E0 (lV) Baseline EEG amplitude 45.0 (4) 45.7 (4) 45.6 (4) 45.2 (4) 41.9 (4)
Emax (lV) Maximal increase in EEG amplitude 31.8 (11) 30.7 (11) 30.5 (11) 34.4 (18) 37.3 (12)
Rtot (nM) Target concentration 1 FIX 1 FIX 1 FIX 1 FIX 1 FIX
slope (lV/
min)
Increase in baseline EEG over time - 0.0276 (15) - 0.0296 (13) - 0.0296 (13) - 0.0273
(14)
0 FIX
x2 E0
(lV)
IIV variance on E0 0.111 (20) 0.116 (20) 0.116 (20) 0.111 (19) 0.129 (18)
r2 prop Variance of proportional error 0.057 (7) 0.0565 (7) 0.0565 (7) 0.0576 (7) 0.0597 (7)
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Discussion
In this study, TB and EC models were compared to
describe the delay between morphine plasma concentra-
tions and EEG effects for three different dose levels. Model
discrimination was difficult to obtain and selection of the
best model (the ECPL model in this study) was only pos-
sible on basis of the objective function value differences.
Moreover, simulations with the TBPL model showed that a
shift in TmaxTO with increasing doses, the distinctive
future of the TB model compared to the EC model, only
occurs for a limited range in parameter values. Both a koff
value much smaller and much larger than the kel value and
a target concentration larger than the initial drug concen-
tration decrease this shift in TmaxTO towards zero.
Since the simulations show that the TmaxTO does not
depend on the dose for koff values much lower than the kel
and target concentrations much higher than the initial drug
concentration, this means that the TBPL model for these
parameter values behaves like an ECPL model, with a first
order increase and decrease in the concentration that is
linked to the effect. Together with the small differences in
EC and TB model fits to the morphine EEG data, this
shows that for many parameter combinations, a TB model
gives rise to similar drug effect profiles as an EC model.
This means that neither a successful fit of a TB or EC
model necessarily supports the relevance of target binding
or target site distribution, respectively, while a single
successful fit is often presented as such support
[11, 23, 39]. To obtain support for one of the two mecha-
nisms, both models should be fitted to the data and com-
pared on basis of objective metrics such as the AIC. This
approach demonstrated the added value of the combined
EC–TBPL model compared to the ECPL and the TBPL
model for buprenorphine and AR-HO47108 [13, 29].
However, this method also demonstrated that the TBPL
model performed similarly as the ECPL model for eight
calcium antagonists [14] and that the EC model performed
similarly as the EC–TBPL model for fentanyl [13]. This
demonstrates that even if objective metrics are used, dis-
crimination between two models is not always possible.
Moreover, obtained model discrimination strictly informs
on the data fit of each model, not directly on the plausibility
of the represented mechanism. This lack of discrimination
between TB and EC models means that a visually satis-
fying model fit of the EC model does not indicate that the
TB will be not applicable. The TB model should therefore
be considered and tested more often as mechanistic
Fig. 4 Schematic representation of the ECECF, TBECF, IEECF and
DEECF model structures that were used to describe the EEG data,
based on brain ECF concentrations. The different structures represent
a the DEECF model, b the ECECF model, c the TBECF model and d the
IEECF model, with ksyn being the zero-order effect generation rate
constant, and kdeg being the first-order effect degradation rate
constant. The distribution from plasma to the tissue compartments
and the brain ECF compartment is described in Supplement S1. The
arrows indicate morphine flows, the dotted line indicates a direct
relationship
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alternative to the EC model to find the best fitting model.
Moreover, the TB model parameters can be measured
partially in vitro/ex vivo, which enables a better in vitro–
in vivo extrapolation (IVIVE).
In this study, the models based on brain ECF concen-
trations did not perform better than the models based on
plasma concentrations. One would expect that the brain
ECF concentrations would reflect the target site concen-
tration better than the plasma concentrations, especially if
brain distribution is relatively slow and nonlinear, as it was
in this study. The inferior performance of the brain ECF-
based models might be explained by the extremely high
variability in the brain ECF data of the 4 mg/kg dose
group, as shown in Figure S5. However, a direct effect
model (DEECF1) could be identified from the brain ECF
concentrations and showed an only 39 points higher AIC
than the best model IEECF1, while an IE model fit could not
be obtained from the plasma concentrations, indicating that
the ECF concentrations reflect the target site concentration
more closely compared to the plasma concentrations. This
is in line with the relevance of drug concentrations in the
brain for CNS effects that has been demonstrated by sev-
eral other studies [40–43] and the difference between
plasma and brain concentrations that has been identified for
several compounds [44]. In all our target binding models, a
linear target occupancy–effect relationship had to be
assumed to keep the model parameters identifiable. Such a
linear relationship has been observed and can be expected
unless for full agonists in tissues with relatively high target
concentrations compared to the concentration of signal
transduction molecules (i.e. for a high receptor reserve)
[24].
Only a one compartment pharmacokinetic model was
used in this study in combination with the simplest TBPL
model to investigate the DTmaxTO. The same principles are
expected to apply if the TBPL model has a two-compart-
ment or three-compartment pharmacokinetic model or with
target turnover and signal transduction models, but the
Table 7 Parameter values and objective function values of the tested models describing the EEG data, based on ECF concentrations
Parameter definition ECPL1 ref.
model
TBECF1
binding model
DEECF1
direct effect
ECECF1 effect
compartment
IEECF1
indirect effect
OFV 25,996.1 26,284.1 26,284.0 26,255.1 26,240.3
AIC 26,118.1 26,300.1 26,300.0 26,273.1 26,258.3
Parameter Parameter definition Value
(%CV)
Value (%CV) Value (%CV) Value (%CV) Value (%CV)
k1e (/min) Distribution to transit compartment 0.0457 (35) – – – –
keo (/min) Distribution from effect compartment 0.0377 (41) – – 0.161 (40) –
k1e–Pgp (/
min)
Distribution to transit with Pgp blocker 0.0647 (36) – – – –
keo–Pgp (/
min)
Distribution from effect with Pgp blocker 0.0155 (77) – – – –
E0 (lV) Baseline EEG amplitude 47.6 (6) 48.9 (6) 48.9 (6) 49.1 (6) 49.1 (6)
Emax (lV) Maximal increase in EEG amplitude 27.5 (20) 32.7 (17) 23.4 (18) 24.9 (19) 25.4
a (36)
Emax–Pgp
(lV)
Maximal increase in EEG amplitude with
Pgp blocker
– 41.6 (14) 43.2 (15) 43.3 (42)
EC50
(nM)
concentration giving half-maximal
increase in EEG amplitude
1100 (87) – 173 (22) 182 (26) 182 (25)
NH Hill factor 2.05 (49) 2.3 (41) 2.02 (43) 2.07 (43)
slope (lV/
min)
Increase in baseline EEG amplitude over
time
- 0.0235
(34)
- 0.0400 (17) - 0.0359
(17)
- 0.0373 (19) - 0.0377 (19)
koff (/min) Dissociation rate constant – 0.0932 (37) – – –
KD Equilibrium constant – 283 (40) – – –
KD–Pgp Equilibrium constant with Pgp blocker – 55.9 (15) – – –
kdeg (/
min)
Degradation rate constant 0.124 (34)
x2 E0
(lV)
Variance of IIV on E0 0.0668 0.0668 (26) 0.072 (25) 0.0696 (26) 0.0961 (26)
r2 prop Variance of proportional error 0.0550 (10) 0.0598 (10) 0.0598 (10) 0.0593 (10) 0.059 (10)
aThis value was estimated as the maximal ksyn minus baseline ksyn (calculated from E0 and kdeg) and calculated by dividing the estimated value by
the kdeg
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parameter range for which TmaxTO shifts with a change in
dose might be different compared to the model used in the
simulations. In analogy to Fig. 7, for the combined EC–TB
model one would expect that to obtain a significant
DTmaxTO and to identify the TB model in addition to the
EC model, the ke0 should be in the same order of
Fig. 5 Overview of the shift in TmaxTO that was observed in the
simulations with the TBPL model (see upper-right corner), as a result
of the change in the affinity-normalized dose (leading to an initial
concentration of 5 and 0.5 times the KD). Each pixel represents a
single simulation in which the koff and kon value correspond to the
position on the y-axis and the x-axis, respectively, and the color
represents the observed shift in TmaxTO in that simulation. The
elimination rate constant kel was 0.03/hr and the target concentration
was 0.1 nM for all simulations in this figure
Fig. 6 Overview of the ratio of TmaxTO values that was observed in
the simulations with the TBPL model (see inset) as a result of the
change in the affinity-normalized dose (leading to an initial concen-
tration of 5 and 0.5 times the KD). Each pixel represents a single
simulation in which the koff and kon value correspond to the position
on the y-axis and the x-axis, respectively, and the color represents the
observed shift in TmaxTO in that simulation. The elimination rate
constant kel was 0.03/hr and the target concentration was 0.1 nM for
all simulations in this figure
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magnitude as the koff if the maximal drug concentration is
around or below the KD. This is indeed the case for the two
successful examples of an EC–TBPL fit: for buprenorphine,
the ke0 was 0.0242/min and the koff was 0.0731/min [13]
and for AR-HO47108, the ke0 was 0.0351 for the drug and
0.00749 for its metabolite and the koff was 0.00303 and
0.00827/min, respectively [29]. On the other hand, the
combined EC–TB model EC–TBPL1 that was identified in
this study for morphine also showed a similar value for ke0
and koff (0.0327 and 0.275, respectively), but this model
was not better than the EC model ECPL1. In comparison
with our one compartment pharmacokinetics model with
intravenous dosing, especially the absorption or the dis-
tribution phase into the target site could pose additional
limiting factors that prevent a shift in TmaxTO with
increasing doses.
One of the most important advantages of the EC model
is that it only requires one parameter, ke0. However, the EC
model most often needs to be combined with an Emax
model, which also requires two or three parameters, Emax,
EC50 and possibly the hill factor. The binding model has
three parameters, kon, koff and Rtot, and needs at least 1
additional parameter, Emax, to convert occupancy predic-
tions to effect predictions. One or two additional parame-
ters might be required to describe a nonlinear target
occupancy-effect relationship, which is required in case of
a high efficacy and receptor reserve [24]. The discrimina-
tion between the two nonlinearities in such cases might be
hard or impossible to obtain. However, kon and koff can be
Fig. 7 Overview of the DTmaxTO that was observed in the simula-
tions as a result of the change in the affinity-normalized dose for
different combinations of parameter values as indicated above the
panels. Each pixel represents a single simulation in which the koff and
kon value correspond to the position on the y-axis and the x-axis,
respectively, and the color represents the observed shift in TmaxTO in
that simulation. All panels vary only one other parameter compared to
the upper left panel
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obtained from in vitro experiments and Rtot from ex vivo
experiments. Especially the identification of Rtot from
ex vivo data can help to reduce the difficulties with
parameter identifiability as often associated with the TB
model [45]. It should be noted that the measurement of
in vitro target binding only helps to explain/describe the
delay between pharmacokinetics and pharmacodynamics if
the target binding kinetics are the rate-limiting step in this
delay in vivo. As biologics often display lower dissociation
rate-constants and their target binding is more often
affecting the pharmacokinetics compared to small mole-
cules, as exemplified by the multitude of TMDD model
applications in this area, one could expect that the TB
model is mostly relevant for biologics. However, small
molecules can also have low dissociation rate-constants, as
exemplified by the irreversible binders aspirin and
omeprazole and the target association-dissociation of the
semi-synthetic opioid buprenorphine. Moreover, the
increasing interest in the pharmaceutical industry to design
small molecules with low dissociation rate-constants can
lead to an increase in the number of such molecules in drug
discovery and development and the associated modeling
efforts.
In summary, the limited difference between TB and EC
models should be taken into account in the evaluation of
historical and the design of new modelling studies. By
informing the TB models with in vitro data, TB models can
help to translate between in vitro and in vivo studies if the
target binding is a rate-limiting step. The combination of
parameter values for which the TmaxTO in the target
binding model is dependent on the dose is limited to koff
values around the elimination rate constant and to target
concentrations lower than the initial drug concentration.
Although the combination of multi-compartment pharma-
cokinetics models, TB models and target turnover models
might affect the parameter range were the TmaxTO is
dependent on the dose, this study is a first indication that
such limitations should be taken into account for under-
standing TB models.
Conclusion
In this study, it was shown that successful fitting of a TB or
EC model is not enough support to assume the relevance of
target binding or target site distribution. Moreover, for a
one-compartment pharmacokinetic model with target
binding, the DTmaxTO for changing doses can only be
identified if the koff has a value around the pharmacokinetic
elimination rate constant and the target concentration is
lower than the initial drug concentration. The TmaxTO is
determined by the rate of target binding relative to the
decline rate of unbound drug and unbound target
concentrations. These findings indicate that the relatively
sparse occurrence of target binding models in literature
does not discredit the relevance of target binding kinetics.
This study also shows that a TB and EC model might be
similar for the tested dose range and pharmacokinetic
conditions, while extrapolation to different conditions
might result in different effect versus time profiles for the
TB and EC model. In conclusion, the identification of the
appropriate model is important and target binding models
should be tested more often to increase the translation
between in vitro and in vivo studies and to increase the
predictive power of developed PKPD models.
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